Pfizer CEO: 2023 will be a 'pivotal year' as COVID-19 drug sales wane
aol.com
news
2022-10-18 19:50:20

Americans are moving on from COVID-19. Most public places, transit, and municipalities have gotten rid of mask mandates. Vaccine booster rates have plateaued, even with the introduction of a new 'bivalent' shot targeting multiple variants, including Omicron.Pfizer (PFE), the giant, legacy drugmaker, along with its partner BioNTech and rival, Moderna (MRNA), saved lives with messenger-RNA-based vaccines that also gave a big boost to profits. Now — to a degree — Pfizer has to move on, too.'Next year for Pfizer is a pivotal year,' Chief Executive Albert Bourla said in an interview at Yahoo Finance's All Markets Summit on Monday.
